A bimatoprost and timolol fixed combination (Ganfort; Allergan) is more effective at lowering intraocular pressure (IOP) over 12 weeks than latanoprost (Xalacom; Pfizer), according to results presented at the meeting of the European Glaucoma Society (EGS), held June 1–6 in Berlin.
A bimatoprost and timolol fixed combination (Ganfort; Allergan) is more effective at lowering intraocular pressure (IOP) over 12 weeks than latanoprost (Xalacom; Pfizer), according to results presented at the meeting of the European Glaucoma Society (EGS), held June 1–6 in Berlin.
Antonio Martinez of the Instituto Gallego de Oftalmologia, Spain and colleagues conducted a prospective, randomized, evaluator masked, single centre crossover study, in which open angle glaucoma (OAG) patients (n=54; eyes=108) received a once daily evening dose of either Ganfort or Xalacom for 12 weeks, following an initial six week treatment regime of twice daily timolol maleate 0.5%. Patients in the Ganfort arm then received a further 12 weeks of treatment with Xalacom, and patients in the Xalacom arm went on to receive 12 weeks of Ganfort treatment. IOP was measured at baseline, and at weeks six and 12 of each treatment period; mean IOP range across a 12-hour period was also evaluated.
After 12 weeks of treatment, subjects had a mean baseline IOP of 22.0 mmHg; 12 hours post-treatment, patients treated with Ganfort had a mean IOP of 17.7 mmHg whereas patients treated with Xalacom had a mean IOP of 18.5 mmHg. Ganfort subjects showed a mean IOP fluctuation range of 4.8 mmHg; in Xalacom-treated patients, the range was 5.9 mmHg.
Thus the researchers concluded that, whilst both treatments are efficacious, Ganfort is slightly more effective than Xalacom in reducing IOP in OAG subjects.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.